Accuray Incorporated (ARAY) Stock Score, Valuation & Financial Research
Accuray Incorporated is in the Healthcare sector and Medical - Devices industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 17/100.
Quick answer for ARAY
Accuray Incorporated currently has a Wall Street Score of 17/100. The stored market price is $0.25. Its financial score is 25/100. Its valuation score is 0/100. These figures are a research snapshot, not a buy or sell recommendation.
What Accuray Incorporated does
Accuray Incorporated specializes in the design, development, production, and sale of advanced radiosurgery and radiation therapy equipment aimed at treating tumors. Their market footprint spans across North and South America, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, China, and the broader Asia Pacific region. Among their core offerings is the CyberKnife System, a sophisticated robotic platform for stereotactic radiosurgery and stereotactic body radiation therapy. This system is employed to target both primary and metastatic tumors located outside the brain, specifically addressing areas such as the spine, breast, kidney, liver, lung, pancreas, and prostate. They also provide the TomoTherapy System, which encompasses the Radixact System, designed to deliver highly precise radiation treatments (up to 50 patients daily) through integrated planning, delivery, an
ARAY financial snapshot
- Wall Street Score:
- 17/100
- Current price:
- $0.25
- Market capitalization:
- $29.8M
- Revenue:
- $401.9M
- Net income:
- $-49.2M
- Free cash flow:
- $-12.8M
- Cash:
- $40.6M
- Total debt:
- $183.9M
- EPS:
- -0.40
- Financial score:
- 25/100
- Valuation score:
- 0/100
- Revenue score:
- 20/100
What stands out
- Reported year-over-year revenue growth is +0.0%.
- Free cash flow is $-12.8M, showing cash burn in the current stored period.
- The balance sheet shows $40.6M of cash versus $183.9M of total debt, so leverage deserves attention.
- The current research record carries a corporate distress warning, which should be reviewed alongside the score.
What the numbers mean
Its current valuation score is 0/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 25/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-09-08.
How to research ARAY
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.